Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Accounts Payables (2024 - 2025)

Maze Therapeutics has reported Accounts Payables over the past 2 years, most recently at $1.8 million for Q4 2025.

  • Quarterly Accounts Payables fell 7.48% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 7.48% year-over-year, with the annual reading at $1.8 million for FY2025, 7.48% down from the prior year.
  • Accounts Payables was $1.8 million for Q4 2025 at Maze Therapeutics, down from $2.9 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $3.7 million in Q2 2025 and troughed at $1.8 million in Q4 2025.